Bulletin
Investor Alert

New York Markets Open in:

Seagen Inc.

NAS: SGEN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jul 29, 2021, 7:55 p.m.

/zigman2/quotes/203326163/composite

$

149.00

Change

+2.05 +1.40%

Volume

Volume 13,283

Quotes are delayed by 20 min

/zigman2/quotes/203326163/composite

Previous close

$ 146.10

$ 146.95

Change

+0.85 +0.58%

Day low

Day high

$144.89

$149.14

Open

52 week low

52 week high

$133.20

$213.94

Open

Company Description

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The c...

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Valuation

P/E Current

43.40

P/E Ratio (with extraordinary items)

40.06

P/E Ratio (without extraordinary items)

52.02

Price to Sales Ratio

14.67

Price to Book Ratio

9.08

Price to Cash Flow Ratio

36.79

Enterprise Value to EBITDA

44.48

Enterprise Value to Sales

13.53

Total Debt to Enterprise Value

0.00

Efficiency

Revenue/Employee

1,039,931.00

Income Per Employee

293,341.00

Receivables Turnover

7.76

Total Asset Turnover

0.70

Liquidity

Current Ratio

7.89

Quick Ratio

7.59

Cash Ratio

6.59

Profitability

Gross Margin

89.99

Operating Margin

27.43

Pretax Margin

28.30

Net Margin

28.21

Return on Assets

19.77

Return on Equity

22.88

Return on Total Capital

21.64

Return on Invested Capital

22.34

Capital Structure

Total Debt to Total Equity

2.14

Total Debt to Total Capital

2.09

Total Debt to Total Assets

1.87

Long-Term Debt to Equity

1.77

Long-Term Debt to Total Capital

1.74

Officers and Executives

Name Age Officer Since Title
Dr. Clay B. Siegall 59 1997 Chairman, President & Chief Executive Officer
Mr. Todd E. Simpson 59 2005 Chief Financial Officer
Dr. Vaughn B. Himes 58 2009 Executive Vice President-Operations
Dr. Roger D. Dansey 63 2018 Chief Medical Officer
Ms. Natasha A. Hernday 47 2011 Senior Vice President-Corporate Development

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
07/02/2021 Clay B. Siegall
President and CEO; Director
5,191   Disposition at $155.7 per share. 808,238
07/02/2021 Clay B. Siegall
President and CEO; Director
7,412   Disposition at $156.43 per share. 1,159,459
07/02/2021 Clay B. Siegall
President and CEO; Director
2,355   Disposition at $157.31 per share. 370,465
07/02/2021 Clay B. Siegall
President and CEO; Director
310   Disposition at $158.29 per share. 49,069
07/02/2021 Charles R. Romp
EVP, Commercial
703   Disposition at $158.41 per share. 111,362
07/02/2021 Clay B. Siegall
President and CEO; Director
5,191   Derivative/Non-derivative trans. at $15.46 per share. 80,252
07/02/2021 Clay B. Siegall
President and CEO; Director
7,412   Derivative/Non-derivative trans. at $15.46 per share. 114,589
07/02/2021 Clay B. Siegall
President and CEO; Director
2,355   Derivative/Non-derivative trans. at $15.46 per share. 36,408
07/02/2021 Clay B. Siegall
President and CEO; Director
310   Derivative/Non-derivative trans. at $15.46 per share. 4,792
07/01/2021 Clay B. Siegall
President and CEO; Director
4,488   Disposition at $156.94 per share. 704,346
07/01/2021 Clay B. Siegall
President and CEO; Director
6,165   Disposition at $157.92 per share. 973,576
07/01/2021 Clay B. Siegall
President and CEO; Director
3,432   Disposition at $158.64 per share. 544,452
07/01/2021 Clay B. Siegall
President and CEO; Director
4,488   Derivative/Non-derivative trans. at $15.46 per share. 69,384
07/01/2021 Clay B. Siegall
President and CEO; Director
6,165   Derivative/Non-derivative trans. at $15.46 per share. 95,310
07/01/2021 Clay B. Siegall
President and CEO; Director
3,432   Derivative/Non-derivative trans. at $15.46 per share. 53,058
06/07/2021 Vaughn B. Himes
Chief Technical Officer
1,303   Disposition at $150 per share. 195,450
06/07/2021 Vaughn B. Himes
Chief Technical Officer
1,303   Derivative/Non-derivative trans. at $26.1 per share. 34,008
06/03/2021 Clay B. Siegall
President and CEO; Director
1,843   Disposition at $142.07 per share. 261,835
06/03/2021 Clay B. Siegall
President and CEO; Director
5,718   Disposition at $142.99 per share. 817,616
06/03/2021 Clay B. Siegall
President and CEO; Director
8,675   Disposition at $143.81 per share. 1,247,551
06/03/2021 Clay B. Siegall
President and CEO; Director
3,900   Disposition at $144.9 per share. 565,110
06/03/2021 Clay B. Siegall
President and CEO; Director
4,551   Disposition at $145.73 per share. 663,217
06/03/2021 Clay B. Siegall
President and CEO; Director
3,866   Disposition at $147 per share. 568,302
06/03/2021 Clay B. Siegall
President and CEO; Director
800   Disposition at $147.71 per share. 118,168
06/03/2021 Vaughn B. Himes
Chief Technical Officer
1,391   Disposition at $147.82 per share. 205,617
06/03/2021 Vaughn B. Himes
Chief Technical Officer
900   Disposition at $147.05 per share. 132,345
06/03/2021 Vaughn B. Himes
Chief Technical Officer
2,800   Disposition at $145.98 per share. 408,744
06/03/2021 Vaughn B. Himes
Chief Technical Officer
1,288   Disposition at $144.61 per share. 186,257
06/03/2021 Vaughn B. Himes
Chief Technical Officer
2,318   Disposition at $143.35 per share. 332,285
06/03/2021 Vaughn B. Himes
Chief Technical Officer
2,000   Disposition at $142.42 per share. 284,840
06/03/2021 Clay B. Siegall
President and CEO; Director
1,843   Derivative/Non-derivative trans. at $15.46 per share. 28,492
06/03/2021 Clay B. Siegall
President and CEO; Director
5,718   Derivative/Non-derivative trans. at $15.46 per share. 88,400
06/03/2021 Clay B. Siegall
President and CEO; Director
8,675   Derivative/Non-derivative trans. at $15.46 per share. 134,115
06/03/2021 Clay B. Siegall
President and CEO; Director
3,900   Derivative/Non-derivative trans. at $15.46 per share. 60,294
06/03/2021 Clay B. Siegall
President and CEO; Director
4,551   Derivative/Non-derivative trans. at $15.46 per share. 70,358
06/03/2021 Clay B. Siegall
President and CEO; Director
3,866   Derivative/Non-derivative trans. at $15.46 per share. 59,768
06/03/2021 Clay B. Siegall
President and CEO; Director
800   Derivative/Non-derivative trans. at $15.46 per share. 12,368
06/03/2021 Vaughn B. Himes
Chief Technical Officer
10,697   Derivative/Non-derivative trans. at $15.46 per share. 165,375
05/27/2021 Vaughn B. Himes
Chief Technical Officer
9,941   Gift at $0 per share. 0
05/27/2021 Vaughn B. Himes
Chief Technical Officer
56,995   Gift at $0 per share. 0
05/27/2021 Vaughn B. Himes
Chief Technical Officer
9,941   Gift at $0 per share. 0
05/27/2021 Vaughn B. Himes
Chief Technical Officer
9,941   Gift at $0 per share. 0
05/27/2021 Vaughn B. Himes
Chief Technical Officer
56,995   Gift at $0 per share. 0
05/17/2021 Charles R. Romp
EVP, Commercial
334   Disposition at $145.95 per share. 48,747
05/14/2021 Marc E. Lippman
Director
1,402   Award at $0 per share. 0
05/14/2021 David W. Gryska
Director
1,402   Award at $0 per share. 0
05/14/2021 Daniel G. Welch
Director
1,402   Award at $0 per share. 0
05/14/2021 Nancy A. Simonian
Director
1,402   Award at $0 per share. 0
05/14/2021 John A. Orwin
Director
1,402   Award at $0 per share. 0
05/14/2021 Alpna H. Seth
Director
1,402   Award at $0 per share. 0
05/14/2021 Ted W. Love
Director
1,402   Award at $0 per share. 0
05/11/2021 Jean I. Liu
GC/EVP, Leg Affairs
1,061   Disposition at $140 per share. 148,540
05/06/2021 Clay B. Siegall
President and CEO; Director
7,723   Disposition at $134.29 per share. 1,037,121
05/06/2021 Clay B. Siegall
President and CEO; Director
18,079   Disposition at $135.11 per share. 2,442,653
05/06/2021 Clay B. Siegall
President and CEO; Director
3,551   Disposition at $135.75 per share. 482,048
05/06/2021 Clay B. Siegall
President and CEO; Director
7,723   Derivative/Non-derivative trans. at $15.46 per share. 119,397
05/06/2021 Clay B. Siegall
President and CEO; Director
18,079   Derivative/Non-derivative trans. at $15.46 per share. 279,501
05/06/2021 Clay B. Siegall
President and CEO; Director
3,551   Derivative/Non-derivative trans. at $15.46 per share. 54,898
04/09/2021 Clay B. Siegall
President and CEO; Director
6,101   Disposition at $141.42 per share. 862,803
04/09/2021 Clay B. Siegall
President and CEO; Director
5,192   Disposition at $142.22 per share. 738,406
04/09/2021 Clay B. Siegall
President and CEO; Director
1,009   Disposition at $143.24 per share. 144,529
04/09/2021 Clay B. Siegall
President and CEO; Director
300   Disposition at $143.95 per share. 43,185
04/09/2021 Clay B. Siegall
President and CEO; Director
6,101   Derivative/Non-derivative trans. at $15.46 per share. 94,321
04/09/2021 Clay B. Siegall
President and CEO; Director
5,192   Derivative/Non-derivative trans. at $15.46 per share. 80,268
04/09/2021 Clay B. Siegall
President and CEO; Director
1,009   Derivative/Non-derivative trans. at $15.46 per share. 15,599
04/09/2021 Clay B. Siegall
President and CEO; Director
300   Derivative/Non-derivative trans. at $15.46 per share. 4,638
/news/latest/company/us/sgen

MarketWatch News on SGEN

  1. Seagen started at in line with $153 stock price target at Evercore ISI

    6:41 a.m. May 17, 2021

    - Tomi Kilgore

  2. Seagen upgraded to buy from neutral at BofA Securities

    11:30 a.m. Jan. 15, 2021

    - Tomi Kilgore

  3. These are the worst-performing stocks in October as Big Tech slumps

    5:14 p.m. Oct. 30, 2020

    - Philip van Doorn

  4. Barron’s Daily: Merger Monday Is Back

    7:51 a.m. Sept. 14, 2020

    - Barron's Online

  5. Gilead reaches $21 billion deal for Immunomedics

    4:30 p.m. Sept. 13, 2020

    - MarketWatch.com

  6. Seattle Genetics stock price target raised to $179 from $150 at J.P. Morgan

    7:45 a.m. July 21, 2020

    - Tomi Kilgore

  7. Charting a bull flag, S&P 500 holds the range top

    11:40 a.m. July 20, 2020

    - Michael Ashbaugh

  8. Loading more headlines...
/news/nonmarketwatch/company/us/sgen

Other News on SGEN

  1. 10-Q: SEAGEN INC.

    5:30 p.m. July 29, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  2. Seagen shares rise after Q2 earnings beat

    4:29 p.m. July 29, 2021

    - Seeking Alpha

  3. Seattle Genetics EPS beats by $0.13, beats on revenue

    4:10 p.m. July 29, 2021

    - Seeking Alpha

  4. Seattle Genetics Q2 2021 Earnings Preview

    5:35 p.m. July 28, 2021

    - Seeking Alpha

  5. Notable earnings after Thursday's close

    5:35 p.m. July 28, 2021

    - Seeking Alpha

  6. IDNA And Healthcare Dashboard For July

    12:02 p.m. July 16, 2021

    - Seeking Alpha

  7. Tracking Baker Brothers Portfolio - Q1 2021 Update

    7:50 a.m. July 8, 2021

    - Seeking Alpha

  8. This Risky Micro-Cap Could Pay Off Big

    8:31 a.m. June 30, 2021

    - Motley Fool

  9. 3 Top Stocks Under $10

    10:03 a.m. June 24, 2021

    - Motley Fool

  10. Seagen: Substantially More Growth For This Stalwart

    10:14 a.m. June 20, 2021

    - Seeking Alpha

  11. 3 Biotech Stocks You'll Be Glad You Bought at These Prices

    6:00 a.m. May 19, 2021

    - Motley Fool

  12. Loading more headlines...

At a Glance

Seagen Inc.

21823-30th Drive SE

Bothell, Washington 98021

Phone

1 4255274000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$2.18B

Net Income

$613.67M

2020 Sales Growth

137.3%

Employees

2,092

/news/pressrelease/company/us/sgen

Press Releases on SGEN

  1. Seagen Reports Second Quarter 2021 Financial Results

    4:02 p.m. July 29, 2021

    - BusinessWire - BZX

  2. Anti-CD19 Market Demand Analysis and Opportunity Outlook 2026

    6:45 a.m. July 29, 2021

    - Market Insight Reports

  3. Loading more headlines...
Link to MarketWatch's Slice.